ARTICLE | Company News
Fate Therapeutics, Stemgent deal
May 11, 2009 7:00 AM UTC
Fate and Stemgent established the Catalyst program to provide induced pluripotent stem (iPS) cell technology to the biotech and pharmaceutical industry in exchange for annual funding. Fate and Stemgen...